Table 3
Open in new tab

Multivariable analysis table comparing breast-conserving surgery + radiotherapy and mastectomy ± radiotherapy for overall survival adjusted for patient demographics, socio-economic deprivation, tumour characteristics, staging, and treatment adjuncts

CharacteristicValueHR (95% c.i.)P
Treatment modality
 BCS + RTx8897 (62.7)1 (reference)
 Mx + RTx2953 (20.9)1.34 (1.20,1.51)<0.001
 Mx − RTx2332 (16.4)1.57 (1.41,1.75)< .001
Age at diagnosis (years)
 <502748 (19.3)1 (reference)
 50–698264 (58.3)1.45 (1.26,1.66)<0.001
 ≥703170 (22.4)3.12 (2.70,3.61)<0.001
Referral
 Symptomatic8195 (57.8)1 (reference)
 Screening4912 (34.6)0.66 (0.59,0.75)<0.001
 Other1075 (7.6)1.17 (1.02,1.35)0.027
Year of diagnosis
 2010–20111837 (13.0)1 (reference)
 2012–20133206 (22.6)0.89 (0.78,1.01)0.078
 2014–20153203 (22.6)0.98 (0.85,1.13)0.805
 2016–20172945 (20.8)0.87 (0.74,1.03)0.106
 2018–20192991 (21.1)0.78 (0.65,0.94)0.008
SIMD category
 Most affluent2735 (19.4)1 (reference)
 Affluent2396 (17.0)0.96 (0.83,1.11)0.574
 Intermediate2472 (17.5)1.09 (0.95,1.26)0.217
 Deprived2936 (20.8)1.12 (0.99,1.28)0.083
 Most deprived3563 (25.3)1.46 (1.29,1.65)<0.001
Tumour grade
 11641 (11.8)1 (reference)
 26528 (47.1)1.03 (0.87,1.21)0.741
 35697 (41.1)1.48 (1.25,1.76)<0.001
Tumour size
 T17271 (51.6)1 (reference)
 T25692 (40.3)1.29 (1.18,1.42)<0.001
 ≥T31135 (8.1)2.06 (1.77,2.40)<0.001
Tumour subtype
 ER+HER2−9654 (68.1)1 (reference)
 ER+HER2+1362 (9.6)1.30 (1.08,1.57)0.006
 ER−HER2+609 (4.3)1.41 (1.05,1.89)0.021
 ER−HER2−1054 (7.4)1.42 (1.11,1.82)0.005
Lymph node status
 N09209 (65.5)1 (reference)
 N1–34850 (34.5)1.63 (1.48,1.80)<0.001
Chemotherapy
 No8325 (58.7)1 (reference)
 Yes5857 (41.3)0.68 (0.60,0.76)<0.001
Biological therapy
 No12 453 (87.8)1 (reference)
 Yes1729 (12.2)0.53 (0.42,0.66)<0.001
Endocrine therapy
 No2601 (18.3)1 (reference)
 Yes11 581 (81.7)0.73 (0.58,0.91)0.006
CharacteristicValueHR (95% c.i.)P
Treatment modality
 BCS + RTx8897 (62.7)1 (reference)
 Mx + RTx2953 (20.9)1.34 (1.20,1.51)<0.001
 Mx − RTx2332 (16.4)1.57 (1.41,1.75)< .001
Age at diagnosis (years)
 <502748 (19.3)1 (reference)
 50–698264 (58.3)1.45 (1.26,1.66)<0.001
 ≥703170 (22.4)3.12 (2.70,3.61)<0.001
Referral
 Symptomatic8195 (57.8)1 (reference)
 Screening4912 (34.6)0.66 (0.59,0.75)<0.001
 Other1075 (7.6)1.17 (1.02,1.35)0.027
Year of diagnosis
 2010–20111837 (13.0)1 (reference)
 2012–20133206 (22.6)0.89 (0.78,1.01)0.078
 2014–20153203 (22.6)0.98 (0.85,1.13)0.805
 2016–20172945 (20.8)0.87 (0.74,1.03)0.106
 2018–20192991 (21.1)0.78 (0.65,0.94)0.008
SIMD category
 Most affluent2735 (19.4)1 (reference)
 Affluent2396 (17.0)0.96 (0.83,1.11)0.574
 Intermediate2472 (17.5)1.09 (0.95,1.26)0.217
 Deprived2936 (20.8)1.12 (0.99,1.28)0.083
 Most deprived3563 (25.3)1.46 (1.29,1.65)<0.001
Tumour grade
 11641 (11.8)1 (reference)
 26528 (47.1)1.03 (0.87,1.21)0.741
 35697 (41.1)1.48 (1.25,1.76)<0.001
Tumour size
 T17271 (51.6)1 (reference)
 T25692 (40.3)1.29 (1.18,1.42)<0.001
 ≥T31135 (8.1)2.06 (1.77,2.40)<0.001
Tumour subtype
 ER+HER2−9654 (68.1)1 (reference)
 ER+HER2+1362 (9.6)1.30 (1.08,1.57)0.006
 ER−HER2+609 (4.3)1.41 (1.05,1.89)0.021
 ER−HER2−1054 (7.4)1.42 (1.11,1.82)0.005
Lymph node status
 N09209 (65.5)1 (reference)
 N1–34850 (34.5)1.63 (1.48,1.80)<0.001
Chemotherapy
 No8325 (58.7)1 (reference)
 Yes5857 (41.3)0.68 (0.60,0.76)<0.001
Biological therapy
 No12 453 (87.8)1 (reference)
 Yes1729 (12.2)0.53 (0.42,0.66)<0.001
Endocrine therapy
 No2601 (18.3)1 (reference)
 Yes11 581 (81.7)0.73 (0.58,0.91)0.006

Values are n (%) unless otherwise indicated. BCS, breast-conserving surgery; RTx, radiotherapy; Mx, mastectomy; SMID, Scottish Index of Multiple Deprivation; ER, oestrogen receptor; HER2, human epidermal growth factor receptor-2.

Table 3
Open in new tab

Multivariable analysis table comparing breast-conserving surgery + radiotherapy and mastectomy ± radiotherapy for overall survival adjusted for patient demographics, socio-economic deprivation, tumour characteristics, staging, and treatment adjuncts

CharacteristicValueHR (95% c.i.)P
Treatment modality
 BCS + RTx8897 (62.7)1 (reference)
 Mx + RTx2953 (20.9)1.34 (1.20,1.51)<0.001
 Mx − RTx2332 (16.4)1.57 (1.41,1.75)< .001
Age at diagnosis (years)
 <502748 (19.3)1 (reference)
 50–698264 (58.3)1.45 (1.26,1.66)<0.001
 ≥703170 (22.4)3.12 (2.70,3.61)<0.001
Referral
 Symptomatic8195 (57.8)1 (reference)
 Screening4912 (34.6)0.66 (0.59,0.75)<0.001
 Other1075 (7.6)1.17 (1.02,1.35)0.027
Year of diagnosis
 2010–20111837 (13.0)1 (reference)
 2012–20133206 (22.6)0.89 (0.78,1.01)0.078
 2014–20153203 (22.6)0.98 (0.85,1.13)0.805
 2016–20172945 (20.8)0.87 (0.74,1.03)0.106
 2018–20192991 (21.1)0.78 (0.65,0.94)0.008
SIMD category
 Most affluent2735 (19.4)1 (reference)
 Affluent2396 (17.0)0.96 (0.83,1.11)0.574
 Intermediate2472 (17.5)1.09 (0.95,1.26)0.217
 Deprived2936 (20.8)1.12 (0.99,1.28)0.083
 Most deprived3563 (25.3)1.46 (1.29,1.65)<0.001
Tumour grade
 11641 (11.8)1 (reference)
 26528 (47.1)1.03 (0.87,1.21)0.741
 35697 (41.1)1.48 (1.25,1.76)<0.001
Tumour size
 T17271 (51.6)1 (reference)
 T25692 (40.3)1.29 (1.18,1.42)<0.001
 ≥T31135 (8.1)2.06 (1.77,2.40)<0.001
Tumour subtype
 ER+HER2−9654 (68.1)1 (reference)
 ER+HER2+1362 (9.6)1.30 (1.08,1.57)0.006
 ER−HER2+609 (4.3)1.41 (1.05,1.89)0.021
 ER−HER2−1054 (7.4)1.42 (1.11,1.82)0.005
Lymph node status
 N09209 (65.5)1 (reference)
 N1–34850 (34.5)1.63 (1.48,1.80)<0.001
Chemotherapy
 No8325 (58.7)1 (reference)
 Yes5857 (41.3)0.68 (0.60,0.76)<0.001
Biological therapy
 No12 453 (87.8)1 (reference)
 Yes1729 (12.2)0.53 (0.42,0.66)<0.001
Endocrine therapy
 No2601 (18.3)1 (reference)
 Yes11 581 (81.7)0.73 (0.58,0.91)0.006
CharacteristicValueHR (95% c.i.)P
Treatment modality
 BCS + RTx8897 (62.7)1 (reference)
 Mx + RTx2953 (20.9)1.34 (1.20,1.51)<0.001
 Mx − RTx2332 (16.4)1.57 (1.41,1.75)< .001
Age at diagnosis (years)
 <502748 (19.3)1 (reference)
 50–698264 (58.3)1.45 (1.26,1.66)<0.001
 ≥703170 (22.4)3.12 (2.70,3.61)<0.001
Referral
 Symptomatic8195 (57.8)1 (reference)
 Screening4912 (34.6)0.66 (0.59,0.75)<0.001
 Other1075 (7.6)1.17 (1.02,1.35)0.027
Year of diagnosis
 2010–20111837 (13.0)1 (reference)
 2012–20133206 (22.6)0.89 (0.78,1.01)0.078
 2014–20153203 (22.6)0.98 (0.85,1.13)0.805
 2016–20172945 (20.8)0.87 (0.74,1.03)0.106
 2018–20192991 (21.1)0.78 (0.65,0.94)0.008
SIMD category
 Most affluent2735 (19.4)1 (reference)
 Affluent2396 (17.0)0.96 (0.83,1.11)0.574
 Intermediate2472 (17.5)1.09 (0.95,1.26)0.217
 Deprived2936 (20.8)1.12 (0.99,1.28)0.083
 Most deprived3563 (25.3)1.46 (1.29,1.65)<0.001
Tumour grade
 11641 (11.8)1 (reference)
 26528 (47.1)1.03 (0.87,1.21)0.741
 35697 (41.1)1.48 (1.25,1.76)<0.001
Tumour size
 T17271 (51.6)1 (reference)
 T25692 (40.3)1.29 (1.18,1.42)<0.001
 ≥T31135 (8.1)2.06 (1.77,2.40)<0.001
Tumour subtype
 ER+HER2−9654 (68.1)1 (reference)
 ER+HER2+1362 (9.6)1.30 (1.08,1.57)0.006
 ER−HER2+609 (4.3)1.41 (1.05,1.89)0.021
 ER−HER2−1054 (7.4)1.42 (1.11,1.82)0.005
Lymph node status
 N09209 (65.5)1 (reference)
 N1–34850 (34.5)1.63 (1.48,1.80)<0.001
Chemotherapy
 No8325 (58.7)1 (reference)
 Yes5857 (41.3)0.68 (0.60,0.76)<0.001
Biological therapy
 No12 453 (87.8)1 (reference)
 Yes1729 (12.2)0.53 (0.42,0.66)<0.001
Endocrine therapy
 No2601 (18.3)1 (reference)
 Yes11 581 (81.7)0.73 (0.58,0.91)0.006

Values are n (%) unless otherwise indicated. BCS, breast-conserving surgery; RTx, radiotherapy; Mx, mastectomy; SMID, Scottish Index of Multiple Deprivation; ER, oestrogen receptor; HER2, human epidermal growth factor receptor-2.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close